In this study, treatment with PCa resulted in upregulation of p53 and p21 and downregulation of CDK2, CDK4, cyclin A, cyclin B1, and cyclin D1 proteins in time- and dose-dependent manners. The gene discussed is CDK4; the disease is posterior cortical atrophy.